<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>60 Degrees Pharmaceuticals, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock</link>
<description>Latest news and press releases for 60 Degrees Pharmaceuticals, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/60-degrees-pharmaceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c65678dffbe2df11afb8.webp</url>
<title>60 Degrees Pharmaceuticals, Inc. Common Stock</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock</link>
</image>
<item>
<title>60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15,</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces 2025 Annual Results</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-2025-annual-results</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-2025-annual-results</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-files-new-dietary-ingredient-notification-ndin-with-fda-for-australian-chestnut-extract</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-files-new-dietary-ingredient-notification-ndin-with-fda-for-australian-chestnut-extract</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-all-patients-cured-of-babesiosis-after-tafenoquine-treatment-in-expanded-use-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-all-patients-cured-of-babesiosis-after-tafenoquine-treatment-in-expanded-use-clinical-trial</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-expands-access-130100046</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-expands-access-130100046</guid>
<pubDate>Mon, 02 Feb 2026 13:01:00 GMT</pubDate>
<description>GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company f</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-exercises-license-130100998</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-exercises-license-130100998</guid>
<pubDate>Wed, 28 Jan 2026 13:01:00 GMT</pubDate>
<description>Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription usesWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FSU) to negotiate an ex</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-partnership-130100895</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-partnership-130100895</guid>
<pubDate>Thu, 22 Jan 2026 13:01:00 GMT</pubDate>
<description>Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international travelers WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new m</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-inc-announces-130100520</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-inc-announces-130100520</guid>
<pubDate>Thu, 15 Jan 2026 13:01:00 GMT</pubDate>
<description>WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-detection-130100479</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-detection-130100479</guid>
<pubDate>Mon, 29 Dec 2025 13:01:00 GMT</pubDate>
<description>Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, tod</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-expansion-130100157</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-expansion-130100157</guid>
<pubDate>Thu, 11 Dec 2025 13:01:00 GMT</pubDate>
<description>6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company’s breakthrough therapy designation request WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Comp</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-clinical-130100047</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-clinical-130100047</guid>
<pubDate>Fri, 21 Nov 2025 13:01:00 GMT</pubDate>
<description>90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company f</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-third-185100973</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-third-185100973</guid>
<pubDate>Thu, 13 Nov 2025 18:51:00 GMT</pubDate>
<description>Q3 2025 net product revenue increased 223% year-over-year to $438 thousandGross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended S</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-no-111400530</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-no-111400530</guid>
<pubDate>Wed, 15 Oct 2025 11:14:00 GMT</pubDate>
<description>Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis,</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-unveils-name-110400751</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-unveils-name-110400751</guid>
<pubDate>Thu, 09 Oct 2025 11:04:00 GMT</pubDate>
<description>Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines f</description>
</item>
<item>
<title>Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/join-60-degrees-pharmaceuticals-exclusive-live-investor-webinar-and-qanda-session-on-october-22</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/join-60-degrees-pharmaceuticals-exclusive-live-investor-webinar-and-qanda-session-on-october-22</guid>
<pubDate>Thu, 02 Oct 2025 13:00:00 GMT</pubDate>
<description>ORLANDO, FLORIDA / ACCESS Newswire / October 2, 2025 / RedChip Companies will host an investor webinar with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)(NASDAQ:SXTPW), a pharmaceutical company focused on developing new medicines for vector-borne ...</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-live-webcast-120200836</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-live-webcast-120200836</guid>
<pubDate>Wed, 03 Sep 2025 12:02:00 GMT</pubDate>
<description>WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will present liv</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-present-h-123100914</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-present-h-123100914</guid>
<pubDate>Thu, 21 Aug 2025 12:31:00 GMT</pubDate>
<description>WASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it will participate in the H.C. Wainwright (HCW) 27th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 8-10, 2025. Dr. Geoff Dow, CEO, will be presenting live on Wednesday, September 10, at 2:30 ET, and Company management</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-selects-icahn-125400926</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-selects-icahn-125400926</guid>
<pubDate>Tue, 19 Aug 2025 12:54:00 GMT</pubDate>
<description>90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosisNo FDA-approved treatment exists for chronic babesiosis, a debilitating illness WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharm</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-second-201400154</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-announces-second-201400154</guid>
<pubDate>Wed, 13 Aug 2025 20:14:00 GMT</pubDate>
<description>A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model$1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 202</description>
</item>
<item>
<title>60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria</title>
<link>https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-tulane-university-120100581</link>
<guid isPermaLink="true">https://6ix.com/company/60-degrees-pharmaceuticals-inc-common-stock/news/60-degrees-pharmaceuticals-tulane-university-120100581</guid>
<pubDate>Thu, 17 Jul 2025 12:01:00 GMT</pubDate>
<description>Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with tick-borne illness such as Lyme disease WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious di</description>
</item>
</channel>
</rss>